Drusolv Therapeutics

9:15 AM - 9:30 AM, Tuesday, October 22, 2019 ・ 2nd Floor
Drusolv Therapeutics is a clinical-stage drug company based in Philadelphia. We are developing a novel, high-dose statin for early intervention in a blinding eye disease called age-related macular degeneration (AMD). AMD is the leading cause of blindness in developed countries, affecting more people than glaucoma and diabetic retinopathy combined. Our product, Ocustatin™, is aimed at patients who are still in the intermediate stage of the disease and currently have very limited options to prevent progression to late-stage vision loss. This is a $4B per year, completely unmet need. Ocustatin was developed at Harvard University and has been validated in a very successful proof-of-concept clinical trial that showed a 75% reduction in progression to late-stage blindness. John Edwards, the founder and CEO of Drusolv, is a serial entrepreneur with extensive experience in AMD.
Company Type:
Company HQ State:
Pennsylvania
Company HQ Country:
United States
Year Founded:
2018
Main Therapeutic Focus:
Lead Product in Development:
Ocustatin
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
1
Speaker
photo
CEO
Drusolv Therapeutics